MedPath

CoverEdge Algorithm Programming Study

Not Applicable
Completed
Conditions
Chronic Pain
Registration Number
NCT02492880
Lead Sponsor
Boston Scientific Corporation
Brief Summary

This is a prospective, on-label, multi-center, non-randomized, exploratory, single-arm study to characterize the effects of programming features of the Boston Scientific Precision Spectra™ Spinal Cord Stimulator (SCS) System using the CoverEdge™ surgical lead.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
15
Inclusion Criteria
  • Subject implanted, on-label, with a commercially approved Boston Scientific Spectra neurostimulation system and at least one CoverEdge or CoverEdge X surgical lead, per local directions for use (DFU).
  • Subject signed a valid, Institutional Review Board (IRB)-approved informed consent form.
  • Subject is 18 years of age or older when written informed consent is obtained.
Exclusion Criteria
  • Subject meets any contraindication in Boston Scientific (BSC) neurostimulation system local DFU.
  • Subject is currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or complete study assessments.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Change in Paresthesia Distribution From Subject Completed Paresthesia Drawing Questionnaireminimum 25 days post IPG implant

Change in paresthesia distribution based on programming parameters

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Barolat Neuroscience

🇺🇸

Denver, Colorado, United States

Albany Medical Center

🇺🇸

Albany, New York, United States

Barolat Neuroscience
🇺🇸Denver, Colorado, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.